Home

FDA: BrainSee Novel Software Is Breakthrough For Noninvasive Detection Of Alzheimer’s Disease At The Early Stage Of Mild Cognitive Impairment

Darmiyan CEO Listed in Health Tech Report 2021 Top 25 Women Leaders in Biotechnology

Darmiyan


Early detection of Alzheimer’s disease & monitoring of MCI

Advancing brain health for 160M people worldwide

With Nobel Laureate approved technology

Darmiyan is developing a commercial diagnostic and prognostic software platform for early detection, monitoring and stratification of Alzheimer’s disease (AD) and other neurodegenerative disorders through an innovative magnetic resonance (MR) image analysis technology. Based on over 40 years of cutting-edge brain research, our technology can precisely quantify and detect changes in brain tissue at the cellular level in every voxel (3D pixel) of a brain MRI scan.

Product

Our first product is BrainSee, an FDA-breakthrough medical software to help doctors with prognosis of MCI patient.

Learn more about BrainSee here.

See blind testing validation results in our white paper

Learn more about the technology

Review our journal publications or watch the video below

Podcast: Riches and Niches of Cognitive Health

Featuring: Dr. Kaveh Vejdani, Chief medical and technology officer at Darmiyan, Mary Furlong from Mary Furlong and Associates. Hosted and moderated by Dr. Allison Sekuler from Baycrest/CABHI

Podcast: Evolving past Alzheimer’s

Featuring: Dr. Kaveh Vejdani, Chief medical and technology officer at Darmiyan. Hosted by Dr. Nate Bergman from Kemper Cognitive Wellness

Selected news highlights

Virtual Microscope

Demo

Contact Us


@DarmiyanInc